ABBV · Earnings call · 2026Q3T · Full report

Rinvoq Hidradenitis Suppurativa Positioning

AbbVie Inc. · 2026-10-30 · Importance 23 · Surprise 24

AbbVie expects Rinvoq Phase III results in hidradenitis suppurativa later this year, with HiSCR 50 as the primary endpoint, and will evaluate pain relief, quality of life and flare reduction alongside the primary measure. Management highlighted oral administration and described Rinvoq as a potential later-line option after advanced therapies, with lutikizumab potentially used earlier. The positioning would resemble AbbVie’s approach in psoriatic arthritis, Crohn’s disease and ulcerative colitis, where Skyrizi is used earlier and Rinvoq later.

Key facts

• AbbVie plans to begin an HS platform study later in 2026 evaluating lutikizumab with its long-acting amylin analog ABBV-295.
• AbbVie expects lutikizumab HS 36-week blinded-extension results next year and regulatory submissions in the second half of 2027.
• AbbVie expects 16-week topline results from the Phase III Rinvoq hidradenitis suppurativa program near the end of 2026.
• AbbVie anticipates the Rinvoq hidradenitis suppurativa readout later in 2026.
• AbbVie will evaluate pain, quality of life and lack of flares, as well as HiSCR, in assessing Rinvoq HS study results.
• AbbVie expects Rinvoq in HS to be an oral second-line option after other advanced therapies, with lutikizumab potentially used earlier.
• AbbVie expects lutikizumab could be used earlier in HS and Rinvoq later, following a treatment sequence similar to Skyrizi and Rinvoq in other conditions.
• AbbVie will capture evidence on pain, quality of life and flares in the Rinvoq study, as it did in the lutikizumab study.